The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,288
Sort by:
Antipsychotic Drugs: Technologies and Global Markets
US$ 2,750.00
... market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological ... of the global market for antipsychotic drugs Analyses of global market trends, with data from ...
September 2018
174 pages
Investigation Report on China's Gliclazide Market, 2018-2022
US$ 2,200.00
... of Servier, the company has been taking the leading position on China's Gliclazide market. Also dominating the market are Servier and Servier ... rising after the drug entered China, and exceeded CNY 200 million in 2017. It is expected that China's Gliclazide market will continue to grow as the ...
September 2018
30 pages
Investigation Report on China's Irbesartan Market, 2018-2022
US$ 2,200.00
... of China's Irbesartan market Market demand for Irbesartan in China Analysis on competition on China's Irbesartan market Analysis on major Irbesartan manufacturers in China Driving forces for China's Irbesartan market from 2018 to 2022 Prospect of China's Irbesartan ...
September 2018
30 pages
Investigation Report on China's Lamivudine Market, 2018-2022
US$ 2,200.00
... : Development environment of China's Lamivudine market Size of China's Lamivudine market Competition pattern of China's Lamivudine market Prices of Lamivudine in China Driving forces and opportunities for China's Lamivudine market Prospect of China's Lamivudine market from ...
September 2018
30 pages
Investigation Report on China's Sildenafil Market, 2018-2022
US$ 2,200.00
... the approval. Therefore, Chinese manufacturers began to launch Sildenafil in 2014. CRI's market investigation shows that China's Sildenafil market is dominated by Pfizer's Viagra, Baiyunshan's Jinge ...
September 2018
30 pages
Drug-Device Combination Products Market by Product (Drug-eluting Stent, Infusion Pump, Photodynamic Therapy, Antimicrobial Wound Dressing, Prefilled Syringe, Drug-eluting Balloon, Nebulizer, Inhaler, Transdermal Delivery System, and Others), Application (Cardiovascular Treatment, Diabetes, Respiratory Problem, Cancer Treatment, Antimicrobial Application, and Others), and End User (Hospital & Clinic, Ambulatory Surgical Center, Home Care Setting, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025
US$ 5,370.00
... the growth of the global drug-device combination products market. Further, rise in geriatric population, technological advancements in drug-device combination product, and surge in homebased healthcare market are the other factors ...
September 2018
244 pages
Orphan Drug Market - Forecasts from 2018 to 2023
US$ 3,950.00
The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017. During the forecast period, prescription sales ...
August 2018
108 pages
Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023
US$ 2,000.00
... “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates ... and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information ...
August 2018
110 pages
Aspergillosis Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Aspergillosis Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Aspergillosis pipeline products. DISEASE OVERVIEW Aspergillus is a general fungus type that causes ...
August 2018
90 pages
Burkholderia pseudomallei Infection Drug Development Pipeline Study, H2 2018
US$ 1,200.00
... is the main challenge in detecting and treating Burkholderia Infections disease. Individuals with low immunity levels and ... Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Burkholderia ...
August 2018
45 pages
Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chagas Disease (American trypanosomiasis) pipeline products. DISEASE OVERVIEW Chagas disease, also known as American Trypanosomiasis, is one of the ...
August 2018
70 pages
Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chikungunya (CHIKV) Infection pipeline products. DISEASE OVERVIEW Chikungunya fever is a viral fever, caused ...
August 2018
90 pages
Chlamydia Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Chlamydia Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chlamydia pipeline products. DISEASE OVERVIEW Chlamydia infections are caused by Chlamydia trachomatis bacteria. Worldwide, the ...
August 2018
60 pages
Cryptosporidiosis (crypto) Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Cryptosporidiosis (crypto) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Cryptosporidiosis (crypto) pipeline products. DISEASE OVERVIEW Cryptosporidium is one of the most widespread intestinal ...
August 2018
30 pages
Diphtheria Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Diphtheria Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Diphtheria pipeline products. DISEASE OVERVIEW Global Diphtheria market is estimated to be around $4.5 billion in 2020 driven ...
August 2018
60 pages
Hepatitis A (HAV) Infection Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Hepatitis A (HAV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Hepatitis A (HAV) Infection pipeline products. DISEASE OVERVIEW The disease is primarily ...
August 2018
35 pages
Hepatitis D (HDV) Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Hepatitis D (HDV) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Hepatitis D (HDV) pipeline products. DISEASE OVERVIEW Hepatitis D virus (HDV) infection is a liver disease ...
August 2018
50 pages
Herpes Labialis Drug Development Pipeline Study, H2 2018
US$ 1,200.00
Herpes Labialis Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Herpes Labialis pipeline products. DISEASE OVERVIEW Herpes Labialis referred to as cold sores, is a widespread infection impacting ...
August 2018
35 pages
